Sign in: Staff/Students
Scientists at the University of Liverpool have uncovered a new target for drugs that could battle a lethal childhood cancer known as neuroblastoma.
Neuroblastoma is one of the deadliest childhood cancers, causing 15% of all paediatric cancer deaths. The majority of sufferers have incurable disease, which has often spread throughout the body when first diagnosed.
Over the past 20 years, long-term survival has improved but children still receive very harsh treatments that not only kill tumour cells but also normal cells. As for many cancers, treatments for neuroblastoma are not specific and patients have limited ability to tolerate such toxic therapies.
It has been known for some years that certain sub-classes of neuroblastoma cancers express gene ‘signatures’ associated with very aggressive tumour behaviour such as rapid growth and spread.
Scientists at the University’s Institute of Integrative Biology at have now discovered that an enzyme protein called sulfatase 2 (Sulf2) is linked to this high-risk cancer-promoting gene signature.
Significantly they showed that lowering the amounts of Sulf2 in human cancer cells strongly reduced their ability to form tumours. Sulf2 is responsible for modifying sulphated sugars called heparan sulphates, found on the surface of cells. They play crucial roles in controlling cell functions, including promoting cell growth and preventing cell death.
New therapies needed
The research, supported by a Medical Research Council (MRC) PhD Fellowship, shows that it could be possible to inhibit this enzyme, potentially slowing or preventing the growth of some neuroblastomas.
Valeria Solari, who led the research as part of the MRC Fellowship, said: “High-risk neuroblastoma is still very difficult to treat and in order to make improvements, we urgently need new therapies.
“Our findings could be exploited in the development of new drugs for neuroblastoma to complement existing treatments.”
Professor Jerry Turnbull, who supervised the Liverpool project, said: “Neuroblastoma is a devastating condition for the affected children and their parents.
“Our research has found that this Sulf enzyme is a key player in making the high-risk forms of neuroblastoma difficult to treat.”
Dr Ed Yates, co-supervisor of the project, added: “The exciting thing about this work is that we now have a new drug development target that has real potential since it is found outside the cancer cells and is accessible to chemical inhibitors.
“We hope that further work will open up new opportunities for treatment of this childhood cancer.”
The research involved an international collaboration with Prof Yves DeClerck at the Los Angeles Childrens Hospital, and is published in the journal Cancer Research.
You must be logged in to post a comment.
All recent news
Year of the Tiger: Celebrations for Lunar New Year 2022
Blog: How I will be celebrating Lunar New Year
New project to explore the ‘hidden world’ of proteins
Researchers confirm dog sickness outbreak in Yorkshire
Treasury minister quits over COVID loan fraud: what we know so far about the unfolding scandal
Tune in to @bbcmerseyside breakfast show tomorrow at around 8.05am to hear Artistic Director @richardhartwell talk about our launch season programme! https://twitter.com/bbcmerseyside/status/1487123308751593479
Researchers are set to harness ground-breaking technologies to explore the 'hidden world' of proteins.
@ClaireEEyers will work with @UniofOxford & @sangerinstitute on the project, which has won £5.5m @BBSRC funding.
@c4pr_liv @LivUniISMIB @KavliOxford https://news.liverpool.ac.uk/2022/01/28/new-project-to-explore-the-hidden-world-of-proteins/
You may have seen recent media reports of a 'mystery illness' affecting dogs in some parts of the UK.
Our @savsnet team has been monitoring the data & confirmed an outbreak of gastrointestinal disease in Yorkshire, although the cause is still unknown.